Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab.
Andrew ChandlerMeredith K BartelsteinTomohiro FujiwaraCristina R AntonescuJohn H HealeyMax VaynrubPublished in: BMC musculoskeletal disorders (2021)
Secukinumab may play a role in bone remodeling for GCTB. Radiologists, surgeons, and pathologists should be aware of this interaction, which can cause lesional ossification. Further research is required to define the therapeutic potential of this drug for GCTB and osteolytic disease.
Keyphrases
- giant cell
- bone mineral density
- ankylosing spondylitis
- postmenopausal women
- soft tissue
- bone loss
- bone regeneration
- body composition
- artificial intelligence
- neoadjuvant chemotherapy
- quality improvement
- stem cells
- locally advanced
- machine learning
- radiation therapy
- thoracic surgery
- lymph node
- adverse drug
- rectal cancer
- replacement therapy
- smoking cessation